The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …

Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

Lineage transitions are a central feature of prostate development, tumourigenesis and
treatment resistance. While epigenetic changes are well known to drive prostate lineage …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined,
due to lack of experimental models that mimic different disease stages. We describe an …

Background Circulating tumour cell (CTC)–derived organoids have the potential to provide a
powerful tool for personalised cancer therapy but are restrained by low CTC numbers …

Organoid technology has provided new translational research opportunities in oncology, in
part by enabling the development of patient-representative living biobanks. Prostate cancer …

The largest US cancer health disparity exists in prostate cancer, with Black men having more
than a two-fold increased risk of dying from prostate cancer compared to all other races. This …